Trial reportThe American journal of clinical nutrition2025
The effect of milk fat globule membrane phospholipid supplementation on cognitive function in older adults with subjective memory complaints-a randomized, double-blind, placebo-controlled trial.
Trial report in The American journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review and Meta-Analysis of Milk Fat Globule Membrane Supplementation for Mental Well-Being.Nutrients · 2026Pooled it
- The Gini coefficient as a surrogate for the regulability or homeostasis of metabolite concentrations: focus on ergothioneine.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Natural Histidine Derivatives-From Basic Research to Potential Applications in Cosmetics and Nutricosmetics.Antioxidants (Basel, Switzerland) · 2026Review
- Is Ergothioneine an Important Source of Plasma TrimethylamineAntioxidants (Basel, Switzerland) · 2026Article
- Potential Protection Against Parkinson's Disease by Ergothioneine-Nature's Multifactorial Neuroprotectant.Antioxidants (Basel, Switzerland) · 2026Review
- Ergothioneine Depletion in Peritoneal Dialysis.Kidney360 · 2026Article
- Current Evidence of Ergogenic and Post-Exercise Recovery Effects of Dietary Supplementation withNutrients · 2026Review
- Antioxidant and Anti-Inflammatory Activities of Probiotic Strains.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMilk fat globule membrane (MFGM) phospholipids have been linked to improved cognitive function, especially in infants, but evidence in healthy older adults is limited.
objectivesThis project investigated MFGM phospholipid supplementation in older adults and focused on clinically meaningful cognitive function and other health-related outcomes.
methodsThis study was a multicenter, repeated-measures, parallel groups, randomized, double-blind, placebo-controlled trial. A total of N = 263 participants aged 55-75 y were randomly assigned to receive: 1) powdered milk fortified with low-dose MFGM (1.7-g phospholipid/d); 2) powdered milk fortified with high-dose MFGM (4.0-g phospholipid/d); or 3) rice starch powder (Control). Randomization used minimization to balance groups across study sites, sex, age, and Montreal Cognitive Assessment scores (MoCA). Participants consumed the product daily for 16 wk and attended their local study site at baseline, week 8, and endpoint. At each visit, they completed various cognitive, behavioral, biochemical, and physical measures.
resultsFor the primary cognitive outcome, Repeatable Battery for Neuropsychological Status (RBANS), there were no significant treatment effects, nor for the secondary cognitive outcome, Computerized Mental Performance Assessment System (COMPASS); however, alertness (Bond-Lader Visual Analogue Scales) was better maintained during cognitive testing at endpoint in the high-dose group. TNF-α was reduced in the high-dose group, whereas γ-aminobutyric acid (GABA) and serotonin increased in both MFGM groups. Cholesterol and low-density lipoprotein (LDL) were also reduced in both MFGM groups. Active B12 increased, and homocysteine tended to decrease in the high-dose group.
conclusionsAlthough no significant effects were evident for cognitive function, subjective alertness during cognitive testing was improved in the high-dose group. Reduced inflammation, cholesterol, and LDL impacts for long-term cardiovascular health, linked with cognitive decline in aging. MFGM supplementation positively impacted active B12 (high and low dose) and homocysteine (high dose only), which have been associated with brain health. Longer study durations are needed to demonstrate cognitive benefits. This trial was registered at Australian New Zealand Clinical Trials Registry as ACTRN12620000270910; www.anzctr.org.au.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.